Henlius and Sandoz Expand Biosimilars Framework in Deal Worth Up to $322 Million
Shanghai Henlius Biotech and Sandoz expanded their biosimilars relationship through a framework covering up to ten proposed monoclonal-antibody or antibody-drug-conjugate biosimilar products or components. Initial terms cover three assets — cetuximab biosimilar HLX05-N, evolocumab…
